I’m not aware of any dosing or safety information. There are different opinions about whether it’s really of much use at this point in the pandemic, but I won’t get into that. It’s not meant for everyone, and it’s meant for early treatment. In Canada, it’s licensed for use in people with mild to moderate COVID-19 who are at increased risk of severe disease. That’s based mainly on study of Paxlovid use in unvaccinated people. The combination has been shown to be beneficial for treating COVID-19 in some types of people, in some circumstances, with the right timing. Paxlovid is a combination of two antiviral drugs, nirmatrelvir and ritonavir, which are both protease inhibitors, neither of which are used in dogs. Treatment is typically a cost-benefit decision, based on assessing potential risks, potential unknowns and potential beneficial effects.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |